#treatment

Expanded access study confirms the long-acting monoclonal antibody works well in people with extensive prior treatment.

Researchers are working on patches containing tiny needles that deliver medications through the skin.

Researchers at George Washington University take a look.

A look at December issues from the POZ archives

Long-acting injectables may be given once every other month, according to new findings.

POZ writers and artists have thrived at the magical intersection of lived experience and boundless talent.

A high proportion of people with HIV suffer from anxiety, which is associated with lower rates of HIV treatment and adherence to treatment.

The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.

The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.

A look at fall issues from the POZ archives

A new analysis of the global START trial found that health outcomes were better for those starting treatment within six months.

CCR5-blocking antibody leads to long-term HIV suppression

Researchers conducted an analysis of hep C treatment outcomes in those also living with HIV in Western nations.

POZ contributing writer Shawn Decker shares his journey from being a kid with no real treatment options to now.

Recently, ViiV Healthcare applied for approval of the first long-acting injectable HIV regimen.